Results 101 to 110 of about 681,398 (156)

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma

Drug Design, Development and Therapy, 2018
Holly L Pacenta, Margaret E Macy Department of Pediatrics, University of Colorado Anschutz Medical Campus and Children’s Hospital Colorado, Aurora, CO, USA Abstract: RTK plays important roles in many cellular signaling processes involved in ...
Pacenta HL, Macy ME
doaj  

Comprehensive characterization and targeted treatment of a pediatric epithelioid glioblastoma with a rare TRIM24-NTRK2 fusion

npj Precision Oncology
High-grade gliomas are one of the most lethal cancers and the leading cause of cancer-related mortality in children. Standard treatment typically involves resection, chemotherapy and radiation, yet offer limited improvement in survival rates.
Simon Keane, Ida Sjöberg, Lily Deland, Angelica Lindlöf, Thomas Olsson Bontell, Teresia Kling, Malin Blomstrand, Henrik Fagman, Jonas A. Nilsson, Daniel Nilsson, Magnus Sabel, Helena Carén, Frida Abel   +12 more
doaj   +1 more source

Case report: NTRK1-rearranged cervical sarcoma with fibrosarcoma like morphology presenting in a 13-year-old managed with a neo-adjuvant TRK-inhibitor and surgical excision. [PDF]

Gynecol Oncol Rep, 2021
Goulding EA, Morreau P, De Silva M, Watson M, van Vliet C, Leung B, Eva LJ.   +6 more
europepmc   +1 more source

Trk Inhibition Reduces Tumorsphere Formation and Changes Expression of Stemness Markers in SK-ES-1 Ewing Sarcoma Cells

Revista Brasileira de Cancerologia
Introduction: Ewing sarcoma (ES) is a highly aggressive type of childhood cancer characterized by a chromosomal translocation resulting in fusions between the gene encoding EWS RNA Binding Protein 1 (EWSR1) and one gene of the ETS family, most ...
Rafael Pereira dos Santos, Bruna Almeida dos Santos, Lauro Gregianin, André Tessainer Brunetto, Algemir Lunardi Brunetto, Rafael Roesler, Caroline Brunetto de Farias   +6 more
doaj   +1 more source

NTRK fusion promotes tumor migration and invasion through epithelial–mesenchymal transition and closely interacts with ECM1 and NOVA1

BMC Cancer
Background The NTRK fusion gene is a rare cancer driver and a typical representative "diamond mutation". Its unique role in tumor progression is highly important for the clinical diagnosis and treatment of patients with tumors.
Siqing Zeng, Ke Jiang, Jie Ge, Mimi Tang, Yuqi Wen, Xiaoting Ma, Heli Liu, Xingui Xiong   +7 more
doaj   +1 more source

Abstract LB-302: Potential role of larotrectinib (LOXO-101), a selective pan-TRK inhibitor, in NTRK fusion-positive recurrent glioblastoma

, 2017
Efforts to develop genomically targeted therapy for glioblastoma (GBM) have been unsuccessful to date. Fusions involving the tropomyosin receptor kinases (TrkA/B/C) encoded by NTRK1/2/3 represent a potential therapeutic target in diffuse gliomas.
Bethany Hanusch, Robert Young, Alexander Drilon, Ryma Benayed, Christian Grommes, Lu Wang, David M. Hyman, Barry S. Taylor, Thomas Kaley, Alison M. Schram, Nora Ku, Jaclyn F. Hechtman   +11 more
core   +1 more source

Abstract 3727: Plasma inhibitory activity (PIA) is a possible pharmacodynamic marker for clinical development of a next generation pan-TRK inhibitor, ONO-5390556

, 2017
Background: Colorectal cancer and Mammary analogue secretory carcinoma harboring Neurotrophic tyrosine receptor kinase (NTRK/TRK) gene rearrangements developed resistance to Entrectinib, ALK/ROS/TRK inhibitor.
Ryohei Kozaki, Ryu Fujikawa, Hikaru Kato, Natsuka Goto, Toshio Yoshizawa   +4 more
core   +1 more source

NTRK-rearranged spindle cell neoplasm of the female genital tract: case report and literature review

Frontiers in Oncology
NTRK-rearranged spindle cell neoplasm is a rare subtype of soft tissue sarcoma that occasionally arises in the lower female genital tract. Accurate diagnosis is clinically important, as these tumors generally display low-grade malignant behavior and may ...
Lulu Feng, Lulu Feng, Lei Li, Lei Li, Yanmei He, Yanmei He, Wei Jiang, Wei Jiang   +7 more
doaj   +1 more source

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors

Therapeutics and Clinical Risk Management, 2018
Dazhi Liu,1 Michael Offin,2 Stephen Harnicar,1 Bob T Li,2 Alexander Drilon2 1Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine ...
Liu D, Offin M, Harnicar S, Li BT, Drilon A   +4 more
doaj  

Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy. [PDF]

J Mol Diagn, 2019
Hsiao SJ, Zehir A, Sireci AN, Aisner DL.
europepmc   +1 more source